Coya Therapeutics shares rise 1.61% intraday after FDA IND clearance for ALS trial and strategic partnerships.
ByAinvest
Wednesday, Sep 3, 2025 2:46 pm ET1min read
COYA--
Coya Therapeutics, Inc. rose 1.61% in intraday trading, with the company's CEO, Arun Swaminathan, discussing recent progress and strategic vision in an exclusive Q&A with PRISM MarketView. The interview highlighted FDA acceptance of the Investigational New Drug (IND) application for COYA 302 in amyotrophic lateral sclerosis (ALS), enabling the initiation of a Phase 2 clinical trial, and strategic partnerships, including with Dr. Reddy’s Laboratories, which provide financial support.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet